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Bone impairment is well described in people living with HIV and taking antiretrovirals 
due to direct and indirect effects of both the virus and 
the medications on bone and immune cells1,2. Osteopenia 
and osteoporosis have a prevalence of up to 67% in this 
population3, and is frequent even in antiretroviral-naïve 
patients2.
Such finding could suggest that unchecked viremia 
affects bone metabolism through its persistent systemic 
inflammatory properties1. However, an in vitro study 
showed that HIV promotes direct osteoblast apoptosis 
through TNF-alpha activation4, providing evidence that 
bone impairment may be explained by viremia itself.
Hence, the use of antiretrovirals with a goal of 
undetectable viral load should lead to higher bone mineral 
density, but some of them may also affect bone metabolism. 
Indeed, a meta-analysis found that osteoporosis had an 
odds ratio of 2.5 in patients treated with antiretrovirals, 
compared to those without treatment3, which suggests that 
such medications are responsible for another component 
of bone loss in HIV patients.
Protease inhibitors are the antiretrovirals that most 
frequently affect bone homeostasis: reduced bone mineral 
density is significantly more common in patients treated 
with such medications, compared to those in other treatment 
schemes3. However, tenofovir alone was also associated 
with increase in bone turnover markers and accelerated 
bone mineral density loss5,6, even when used in the absence 
of HIV infection7.
In addition to affecting bone resorption, tenofovir 
may also induce proximal renal tubular toxicity and 
hypophosphatemic osteomalacia8, another factor that 
could contribute to bone alterations in HIV patients. 
Increased tenofovir concentrations in proximal renal tubule 
cells induces mitochondrial dysfunction, which leads to 
phosphate depletion9. Tenofovir-induced proximal renal 
tubular acidosis has an estimated prevalence of 17% in HIV-
infected patients taking the drug8, and may appear years 
after treatment initiation10. Approximately 0.5% develop 
hypophosphatemic osteomalacia, especially if its use is 
concomitant with ritonavir-boosted protease inhibitors and 
non-steroidal anti-inflammatories11. 
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The most common clinical finding is diffuse bone 
pain due to multiple stress fractures11, and should be 
suspected whenever low phosphate serum levels, increased 
alkaline phosphatase and increased fractional excretion 
of phosphate are found, which rule out osteoporosis, that 
presents without electrolyte laboratory alterations12. Making 
the right diagnosis prevents inappropriate treatment with 
bisphosphonates, which depletes even more phosphorus, 
leaving no substrate with which to mineralize the bone, 
worsening pain and fractures.
Therefore,  cl inicians should be aler t  to 
hypophosphatemic osteomalacia in patients with low 
BMD receiving tenofovir, since it can be easily mistaken 
and incorrectly treated as osteoporosis, worsening bone 
pain, fractures and hypophosphatemia.
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